Short answer
Penumbra Inc (PEN) filed its Q1 2016 10-Q quarterly report on May 9, 2016 for the quarter ended Mar 31, 2016.
Penumbra Inc Q1 2016 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $57.9M, up 48.7% YoY from $39.0M
- Gross margin 68.9% vs 68.6%; operating margin 3.2% vs 10.2%
- Best segment Peripheral Vascular: $16.6M, up 127.9%; Neuro: $41.3M, up 30.4%
- Cash $17.6M vs $19.5M; operating cash flow used $3.6M, capital expenditures $1.1M
- Outlook: continued investment in products, manufacturing and international expansion; competition and quarterly variability remain headwinds
Risk Factors
- No material changes: 2015 Form 10-K risk factors remain applicable
- Regulatory risk: Medical-device compliance requirements may constrain operations
- Legal risk: Product-liability claims could materially affect results
- Market risk: Intense competition may pressure growth and profitability
- Financial risk: Dependence on limited operating history increases uncertainty
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Penumbra Inc quarterly reports
- Q3 2019 10-QFiled Nov 7, 2019
- Q2 2019 10-QFiled Aug 6, 2019
- Q1 2019 10-QFiled May 7, 2019
- Q3 2018 10-QFiled Nov 5, 2018
- Q2 2018 10-QFiled Aug 7, 2018
- Q1 2018 10-QFiled May 8, 2018
- Q3 2017 10-QFiled Nov 7, 2017
- Q2 2017 10-QFiled Aug 8, 2017
- Q1 2017 10-QFiled May 9, 2017
- Q3 2016 10-QFiled Nov 3, 2016
- Q2 2016 10-QFiled Aug 9, 2016
- Q3 2015 10-QFiled Nov 12, 2015
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.